About Pricing FAQs Providers Trials Blog

Back to your record

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Lymphoma Clinical Trials in Michigan | 508 Studies

Clinical Trials LymphomaMichigan

Lymphoma Clinical Trials in Michigan

Find 508 clinical trials for lymphoma near Michigan. Connect with research centers in your area.

All Lymphoma trials nationwide All trials in Michigan

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4Not applicable

Who can join

Healthy volunteers too

Showing 141-160 of 508 trials

CompletedBone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)Bone marrow transplants are one treatment option for people with leukemia or lymphoma.NCT00849147·Duarte, California and 16 others Active not recruitingA Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell LymphomaThis is a Phase 1/1b, open-label, first in human study of CPI-818, an oral interleukin-2-inducible tyrosine kinase (ITK) inhibitor for the treatment of relapsed/refractory (R/R)…NCT03952078·Palo Alto, California and 21 others

Lymphoma Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

CompletedSamotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)This phase II Pediatric MATCH trial studies how well samotolisib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with TSC or PI3K/MTOR…NCT03213678·Birmingham, Alabama and 126 others

TerminatedRituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System LymphomaRATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and kill them or carry cancer-killing substances to them.NCT00335140·Stanford, California and 67 others

CompletedA Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell LymphomaThis is a single-arm, open-label, multicenter, clinical trial to evaluate the efficacy and safety of brentuximab vedotin (SGN-35) as a single agent in patients with relapsed or…NCT00866047·Birmingham, Alabama and 21 others

CompletedA Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)The purpose of this study is to evaluate zilovertamab vedotin with respect to objective response rate and duration of response per Lugano Response Criteria as assessed by blinded…NCT05144841·Orange, California and 70 others

CompletedA Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin LymphomaThis study will evaluate the safety, pharmacokinetics, and preliminary efficacy of mosunetuzumab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone…NCT03677141·Birmingham, Alabama and 40 others

TerminatedAvelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)Study B9991011 is a multi-center, international, randomized, open label, 2 component (Phase 1b followed by Phase 3), parallel-arm study of avelumab in combination with various…NCT02951156·Duarte, California and 28 others

Active not recruitingA Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular LymphomaB-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections).NCT05451810·Mobile, Alabama and 71 others

CompletedDevelopment of Strategies to Increase Enrollment in Clinical Trials for Children With CancerRATIONALE: Taking part in a clinical trial may help children with cancer receive more effective treatment.NCT00002485·Sacramento, California and 30 others

Active not recruitingA Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone LymphomaThe purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R\^2) in participants with relapsed/refractory (R/R)…NCT05100862·Fresno, California and 263 others

CompletedNKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin LymphomaPatients will receive intravenous (IV) NKTR-255 in 21 or 28 day treatment cycles.NCT04136756·Goodyear, Arizona and 12 others

TerminatedDasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin LymphomaThis study uses a drug called dasatinib to produce an anti-cancer effect called large granular lymphocyte cellular expansion.NCT01609816·Detroit, Michigan

Active not recruitingTesting the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell LymphomasThis phase II/III trial tests whether it is possible to decrease the chance of high-grade B-cell lymphomas returning or getting worse by adding a new drug, venetoclax to the usual…NCT03984448·Birmingham, Alabama and 633 others

CompletedA Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin LymphomasThe study will be conducted in compliance with the International Council for Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good…NCT03575351·Scottsdale, Arizona and 53 others

CompletedA Study in Participants With Moderate to Severe PsoriasisThe primary purpose for this study is to help answer the following research questions * The safety of ixekizumab (LY2439821) and any side effects that might be associated with it.NCT01107457·Bakersfield, California and 33 others

CompletedEtanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell TransplantThis phase II trial is studying how well etanercept works in treating young patients with idiopathic pneumonia syndrome after undergoing a donor stem cell transplant.NCT00309907·Birmingham, Alabama and 25 others

CompletedTREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's DiseaseThis study is designed to determine the effect of 2 gram/day of ethyl-EPA on motor (movement) signs and symptoms of Huntington disease.NCT00146211·Birmingham, Alabama and 40 others

Active not recruitingInotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic LeukemiaThis phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblastic leukemia that…NCT02981628·Birmingham, Alabama and 156 others

CompletedSafety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell LymphomaTo characterize safety, tolerability and to establish the maximum tolerated dose (MTD) of Tenalisib in combination with Romidepsin in patients with R/R T-cell lymphoma.NCT03770000·Los Angeles, California and 14 others

PreviousPage 8 of 26Next

Other Conditions in Michigan

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia